Breast Cancer Clinical Trials

Showing 4061-4080 of 5,114 trials

A Dose Increase Finding Study of Doxorubicin Hydrochloride Liposome Injection for Patients With Breast Cancer

NCT03017404

To study the maximum tolerated dose of Doxorubicin Hydrochloride Liposome Injection combination with cyclophosphamide and sequential treatment of docetaxel for patients with locally advanced breast cancer

Breast Cancer

Hebei Medical University Fourth Hospital18 participantsStarted May 2015

Shijiazhuang, Hebei, China

UNKNOWNPhase 1

Safety and Pharmacokinetic Study of MM-302 in Patients With Advanced Breast Cancer

NCT01304797

This study is a Phase 1 and pharmacologic open-label dose-escalation trial using a "3+3" design. Successive cohorts of three or more patients will be treated at escalating doses until a maximum tolerated dose is identified. Once the maximum tolerated dose is identified, an Expansion Cohort will be enrolled at that dose to further characterize safety and pharmacologic endpoints. Additional arms will be enrolled to explore the combination of MM-302 with trastuzumab or trastuzumab plus cyclophosphamide in patients with advanced HER2 positive breast cancer.

Breast Cancer

Merrimack Pharmaceuticals75 participantsStarted Mar 2011

San Francisco, California, United States • Indianapolis, Indiana, United States • Boston, Massachusetts, United States +2 more locations

A Dose Increase Finding Study of Doxorubicin Hydrochloride Liposome Injection for Patients With Breast Cancer

Safety and Pharmacokinetic Study of MM-302 in Patients With Advanced Breast Cancer

Related Searches

Study of the Effect of Eplerenone on Heart Function in Women Receiving Anthracycline Chemotherapy for Breast Cancer

Patient Perception of Mammogram Guidelines

3-Dimensional Conformal Radiation Therapy In Treating Women With Stage I or Stage II Breast Cancer Previously Treated With Lumpectomy and Axillary Node Dissection

A Study of Herceptin (Trastuzumab) in Combination With a Taxane in Participants With HER2-Positive Breast Cancer Who Relapsed After (Neo)Adjuvant Herceptin Treatment

Celecoxib in Treating Postmenopausal Women Who Are Undergoing Surgery for Invasive Breast Cancer

Efficacy of Thoracic Paravertebral Block in the Reduction of Acute Post-surgical Pain in Patients With Breast Cancer

Specimen X-Rays of Removed Axillary Lymph Nodes to Guide Pathological Sampling

Doxorubicin-associated Cardiac Remodeling Followed by CMR in Breast Cancer Patients

A Dose-Finding Study of Subcutaneous Herceptin (Trastuzumab) in Healthy Male Volunteers and Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Females

A Study of PI3-Kinase Inhibitor GDC-0941 in Combination With Paclitaxel, With and Without Bevacizumab or Trastuzumab, and With Letrozole, in Participants With Locally Recurrent or Metastatic Breast Cancer

Study of Lurbinectedin (PM01183) in Combination With Capecitabine in Patients With Metastatic Breast Cancer (MBC), Pancreatic Cancer (PC) or Metastatic Colorectal Cancer (CRC).

Irinotecan and Docetaxel in Treating Patients With Refractory Metastatic Breast Cancer

Irinotecan and Cetuximab in Treating Patients With Metastatic Breast Cancer

Circulating MicroRNA as Biomarker of Cardiotoxicity in Breast Cancer

Docetaxel, Capecitabine, and Bevacizumab in Treating Patients With Metastatic Breast Cancer

LY231514 Plus Gemcitabine in Treating Women With Metastatic Breast Cancer

Docetaxel and Carboplatin in Treating Women With Metastatic Breast Cancer

Ixabepilone + Carboplatin Metastatic Breast Cancer